Allurion Technologies (ALUR) Projected to Post Earnings on Wednesday

Allurion Technologies (NYSE:ALUR) is expected to announce its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $3.10 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 8:30 AM ET.

Allurion Technologies Stock Down 12.9%

Shares of NYSE ALUR opened at $0.69 on Wednesday. Allurion Technologies has a 52 week low of $0.23 and a 52 week high of $3.42. The firm has a 50-day moving average price of $0.77 and a 200 day moving average price of $1.26. The stock has a market capitalization of $10.31 million, a price-to-earnings ratio of -0.07 and a beta of -0.18.

Analyst Ratings Changes

A number of brokerages have issued reports on ALUR. Chardan Capital set a $3.00 target price on shares of Allurion Technologies and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Loop Capital set a $3.00 price target on shares of Allurion Technologies in a research report on Tuesday, February 24th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Allurion Technologies in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $3.00.

Institutional Investors Weigh In On Allurion Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of ALUR. XTX Topco Ltd grew its holdings in shares of Allurion Technologies by 43.2% during the second quarter. XTX Topco Ltd now owns 18,670 shares of the company’s stock worth $45,000 after buying an additional 5,633 shares in the last quarter. State Street Corp grew its holdings in shares of Allurion Technologies by 76.2% during the fourth quarter. State Street Corp now owns 26,135 shares of the company’s stock worth $32,000 after buying an additional 11,300 shares in the last quarter. Hudson Bay Capital Management LP purchased a new stake in shares of Allurion Technologies during the fourth quarter worth about $74,000. Heights Capital Management Inc. purchased a new stake in shares of Allurion Technologies during the fourth quarter worth about $74,000. Finally, Armistice Capital LLC purchased a new stake in shares of Allurion Technologies during the fourth quarter worth about $74,000. 21.39% of the stock is currently owned by hedge funds and other institutional investors.

Allurion Technologies Company Profile

Allurion Technologies is a medical technology company specializing in non-surgical weight-loss solutions. The company’s flagship product, the Allurion Gastric Balloon, is a swallowable, fluid-filled device designed to promote weight loss by creating a sense of fullness in the stomach. Unlike traditional intragastric balloons, the Allurion device does not require endoscopic insertion or removal, as it self-deflates and is naturally expelled after treatment, simplifying the patient experience and reducing clinical resource requirements.

In addition to its gastric balloon, Allurion has developed a comprehensive digital health platform that integrates wireless tracking devices, a mobile application, and remote coaching to support patients throughout their weight-loss journey.